Status: Recruiting
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Participants needed: 400
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Scleroderma Research Foundation, Inc.Updated: Feb 4, 2026Locations: 34
Eligibility criteria
Male or female 18+ years of age at the time of signed informed consent; [+6]
Presence of clinically significant pulmonary abnormalities inconsistent with ILD... [+18]